A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer

Ghafouri‐Fard, Soudeh; Khoshbakht, Tayybeh; Hussen, Bashdar Mahmud; Taheri, Majzoubeh; Mokhtari, Majid

doi:10.3389/fonc.2021.777849

Cited by 8 publications

(9 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, information regarding the role of LMNTD2‐AS1 and KLRK1‐AS1 in cancer development is still unknown. AFAP1‐AS1 is a rising star in lncRNA and its function has been summarized in some excellent reviews 33,50 . In our study, we found that AFAP1‐AS1 also has a metabolic impact on CRC.…”

Section: Discussionsupporting

confidence: 57%

See 1 more Smart Citation

Construction of a prognostic glycolysis‐related lncRNA signature for patients with colorectal cancer

Zhong

Wang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Aerobic glycolysis is a common metabolic phenotype in tumors that helps cancer cells adjust to severe living conditions and can aid metastasis in several types of carcinomas, including colorectal cancer (CRC). Long non‐coding RNAs (lncRNAs) can influence tumor biology and have been previously used to assess patients' outcomes and to identify potential therapeutic targets. However, despite the importance of glycolysis‐related lncRNAs (GRLs) in the development of CRC, studies on their use as prognostic markers are still limited. Herein, we applied a series of bioinformatic analyses to screen potential prognostic lncRNAs for colorectal cancer. Out of all lncRNAs screened, nine GRLs were selected to constitute a prognostic signature. Based on the signature, two molecular subtypes were classified with distinct prognostic outcomes and excellent diagnostic accuracy (The 1‐, 3‐ and 5‐year AUC are 0.756, 0.716, and 0.721, respectively). The prognostic value of this signature was further validated using another cohort. The enriched molecular pathways, immune infiltration, and mutation landscape were also significantly different between the two groups. The different drug sensitivity results between the two groups suggest a potential strategy for precise treatment. Furthermore, we confirmed that AFAP1‐AS1 could regulate aerobic glycolysis and metastasis of CRC cells. Overall, we developed a glycolysis‐related lncRNA (GRL) signature and suggested that this signature could offer a predictive value and identify potential therapeutic targets for cancer therapy.

show abstract

Section: Discussionsupporting

confidence: 57%

“…AFAP1‐AS1 is a rising star in lncRNA and its function has been summarized in some excellent reviews. 33 , 50 In our study, we found that AFAP1‐AS1 also has a metabolic impact on CRC.…”

Section: Discussionsupporting

confidence: 53%

Construction of a prognostic glycolysis‐related lncRNA signature for patients with colorectal cancer

Zhong

Wang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…AFAP1-AS1 was upregulated in almost all kinds of malignant tissues, such as lung cancer [ 24 , 25 ], breast cancer [ 16 , 26 ], and osteosarcoma [ 27 ]. Its upregulation had a significant impact on increasing malignancy and decreasing the survival of patients [ 28 ]. Primarily, overexpression of AFAP1-AS1 was found in TNBC tissues and cells, exerting oncogenic activity, and was associated with poor survival in TNBC patients [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

SP1-Induced Upregulation of LncRNA AFAP1-AS1 Promotes Tumor Progression in Triple-Negative Breast Cancer by Regulating mTOR Pathway

Li,

Xian,

Huang

et al. 2023

IJMS

View full text Add to dashboard Cite

The long non-coding RNA (lncRNA) actin fiber-associated protein-1 antisense RNA 1 (AFAP1-AS1) exerted oncogenic activity in triple-negative breast cancer (TNBC). We designed this study and conducted it to investigate the upstream regulation mechanism of AFAP1-AS1 in TNBC tumorigenesis. In this work, we proved the localization of AFAP1-AS1 in the cytoplasm. We elucidated the mechanism by which the transcription factor specificity protein 1 (SP1) modulated AFAP1-AS1 in TNBC progression, which has yet to be thoroughly studied. Dual luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay revealed a strong affinity of SP1 toward the promoter regions P3 of AFAP1-AS1, proving the gene expression regulation of AFAP1-AS1 via SP1 in TNBC. Additionally, SP1 could facilitate the tumorigenesis of TNBC cells in vitro and in vivo by regulating the AFAP1-AS1 expression. Furthermore, silenced AFAP1-AS1 suppressed the expression of genes in the mTOR pathway, such as eukaryotic translation initiation factor 4B (EIF4B), mitogen-activated protein kinase-associated protein 1 (MAPKAP1), SEH1-like nucleoporin (SEH1L), serum/glucocorticoid regulated kinase 1 (SGK1), and its target NEDD4-like E3 ubiquitin protein ligase (NEDD4L), and promoted the gene expression of s-phase kinase-associated protein 2 (SKP2). Overall, this study emphasized the oncogenic role of SP1 and AFAP1-AS1 in TNBC and illustrated the AFAP1-AS1 upstream interaction with SP1 and the downstream modulatory of mTOR signaling, thus offering insights into the tumorigenesis mechanism in TNBC.

show abstract

“…This result combined with the existing high level of expression, we found that AFAP1-AS1 had the possibility of promoting tumorigenesis. Previously, many papers have indicated that AFAP1-AS1 might act as oncogene in human cancers [13]. For example, in colorectal cancer, AFAP1-AS1 is notably increased, and AFAP1-AS1 knockdown inhibits the malignant behavior of cancer cells through targeting miR-195-5p/WISP1 axis [14].…”

Section: Discussionmentioning

confidence: 99%

N6-methyladenosine modified AFAP1-AS1 accelerates hepatocellular carcinoma proliferation and migration via miR-195-5p/KIAA1429 feedback loop

Fan

Ahati

2022

Preprint

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) acts as a dominating malignant tumor with high-mortality rate and poor prognosis. Emerging evidence suggests that N6-methyladenosine (m6A) plays critical roles in HCC progression. However, function of m6A and lncRNA in HCC progression requires further clarification. In our study, we found that AFAP1-AS1, a m6A-modified lncRNA, substantially elevated in the HCC cells and correlated with poor prognosis. Interestingly, AFAP1-AS1 had m6A modification site and m6A writer KIAA1429 bound with the m6A site to enhance AFAP1-AS1 stability. Functionally, AFAP1-AS1 promoted HCC migration/ proliferation and knockdown of AFAP1-AS1 repressed the tumor growth. Mechanistically, AFAP1-AS1 up-regulated KIAA1429 expression through sponging miR-195-5p, forming positive feedback of KIAA1429/m6A/AFAP1-AS1/miR-195-5p. In summary, our study reveals a new mechanism for AFAP1-AS1-promoted HCC progression, contributing to overcoming HCC tumorigenesis.

show abstract

A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer

Cited by 8 publications

References 77 publications

Construction of a prognostic glycolysis‐related lncRNA signature for patients with colorectal cancer

Construction of a prognostic glycolysis‐related lncRNA signature for patients with colorectal cancer

SP1-Induced Upregulation of LncRNA AFAP1-AS1 Promotes Tumor Progression in Triple-Negative Breast Cancer by Regulating mTOR Pathway

N6-methyladenosine modified AFAP1-AS1 accelerates hepatocellular carcinoma proliferation and migration via miR-195-5p/KIAA1429 feedback loop

Contact Info

Product

Resources

About